Therefore, AZD1775 is effective as a single agent in ER+ breast cancer cells that are resistant to antiestrogen and CDK4/6 inhibitors but the anti-proliferative effect of WEE1 inhibition in these cells is hampered when combined with antiestrogens or CDK4/6 inhibitors. Here, ESR1 is linked to breast carcinoma.